Kexing Biopharm’s GB18 project received clearance of IND application from NMPA and FDA

On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed innovative product, GB18. Moreover, GB18 has previously received the clearance from U.S. Food and Drug Administration (FDA) for IND application on May 21st. 


GB18 is an innovative biologic product developed for the treatment of cancer cachexia, a complication with a prevalence up to 40% to 70% among cancer patients. Currently, no specific biological therapies are available to address the condition, presenting vast market potential. Featuring a unique nanobody-Fc fusion molecular structure, the product demonstrates enhanced stability, bettered bioavailability, and significantly improved performance in inhibiting   disease-associated signaling pathways.


Benchmarking against globally leading pipelines with the same target (GDF-15) and indication, Kexing Biopharm's GB18 features a special nanobody-Fc fusion structure (VHH-Fc), with the patents granted or applied for the molecule globally already. Last October, a research article of GB18’s preclinical study was published in the renowned international academic journal mAbs, which demonstrated that GB18 effectively alleviated weight loss in cancer cachexia models, showing superior weight recovery and improved muscle fibers in both quantity and size compared to the comparator.


In cancer cachexia, the expression level of GDF-15 is significantly elevated, which is closely associated with tumor progression and the severity of cachexia. Therefore, targeting GDF-15 has emerged as a new strategy in addressing the clinical challenge of cancer cachexia. This recent FDA IND approval marks a significant milestone in the Company's globalization of innovative products.


Approximately millions advanced cancer patients annually in the world are suffering from cachexia. There is a significant unmet clinical need for the indication of cancer cachexia.Kexing Biopharm will remain steadfast in its mission to deliver "Precise Products, Predictable Effects, and Health Protection", with a focus on product quality and a commitment to scientific innovation, and improve the lives of patients worldwide.

https://www.kexingbiopharm.com/about.html
Kexing Biopharm

  • Related Posts

    Chinesia Helps Global Learners Build Practical Chinese Skills Through One Connected Learning Platform
    • adminadmin
    • November 20, 2026

    Chinese learning designed for real communication Many learners can recognize Chinese words and grammar but still feel uncertain when they need to speak in real situations. Chinesia is designed to…

    Continue reading
    CRET Technology Explained: How Wash-Free Homogeneous CLIA Works
    • adminadmin
    • November 20, 2026

    Industry Background and the Diagnostic Challenge In vitro diagnostic (IVD) testing has long relied on chemiluminescence immunoassay (CLIA) systems that depend on magnetic bead separation, multiple washing steps, and complex…

    Continue reading

    Leave a Reply

    Mechanical Equipment & Tool Parts

    CNC Machining Services for Performance Hardware Brands, 2026

    • November 20, 2026

    Shenzhen Servo Motor Driver Manufacturer CNC Machining 2026

    • November 20, 2026

    CNC Machining Service Pricing and NDA Protection Explained

    • November 20, 2026

    Sports Lighting Energy Management: How to Reduce Operating Costs Without Compromising Lighting Quality

    • November 20, 2026

    Which HVDC Suppliers Balance Efficiency And Lifecycle Cost

    • November 20, 2026

    Aokai 10 mg Filter Bags: Baghouse Emission Control Quotes

    • November 20, 2026